Chemoimmunotherapy
Chemoimmunotherapy is a cancer-treatment strategy that combines cytotoxic chemotherapy with immunotherapy, most commonly an immune checkpoint inhibitor or another immune-modulating treatment.
Chemoimmunotherapy is a cancer-treatment strategy that combines cytotoxic chemotherapy with immunotherapy, most commonly an immune checkpoint inhibitor or another immune-modulating treatment. Chemotherapy can reduce tumor burden and may promote immunogenic cell death, antigen release, and changes in the tumor microenvironment, while immunotherapy is intended to enhance or restore antitumor immune activity. The combined approach is therefore used to address both tumor-cell proliferation and immune escape.
The specific regimen depends on the cancer type, disease stage, biomarkers, and treatment setting. In current research, chemoimmunotherapy is being evaluated in advanced non-small cell lung cancer, small-cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, thoracic tumors, and other malignancies. Commonly studied components include cisplatin, paclitaxel, pembrolizumab, and other checkpoint inhibitors. Outcomes of interest include objective response rate, progression-free survival, overall survival, hazard ratios, lymphopenia, and changes in the tumor microenvironment. Related strategies include combining chemoimmunotherapy with thoracic radiotherapy or using local delivery systems designed to enhance immunogenic cell death.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
11 papers study chemoimmunotherapy directly. The themes below are drawn from those 11. 1 new direction follows.
-
Immunochemotherapy in Lung Cancer : First-line immunochemotherapy in advanced lung cancer is being refined by adding thoracic radiotherapy in selected older patients and using ctDNA tumor fraction to guide regimen choice. Progression-free and overall survival remain key endpoints. 4 papers · 36.4%
-
Immune-Enhanced Cancer Treatment : Combination chemoimmunotherapy is moving toward neoadjuvant treatment, local drug delivery and tumor-targeted probiotics. Hydrogels and engineered microbes aim to improve antigen presentation and immunological memory, while clinical studies test efficacy with or without radiotherapy. 4 papers · 36.4%
-
Others — Cancer Treatment Outcomes : Clinical outcome reporting links venetoclax combinations in untreated CLL, long-term neuroblastoma outcomes and SMARCA4-deficient thoracic-tumor metastases. No shared therapeutic direction emerges. 3 papers · 27.3%
Time-of-day administration makes chemoimmunotherapy a circadian treatment variable
The NSCLC chronotherapy commentary examines the timing of chemoimmunotherapy delivery rather than changing its drugs, disease setting, or delivery vehicle. It reports that earlier administration in the prospective LungTIME-C01 trial nearly doubled progression-free survival, while cautioning that the effect may reflect cytotoxic chronopharmacology, circadian immune regulation, or healthcare-delivery factors rather than immunotherapy timing alone. This gives chemoimmunotherapy a new role as a schedule-dependent intervention and motivates trials that separately test chemotherapy timing, immunotherapy timing, and their interaction 42258320Jun.
Recent Findings on Chemoimmunotherapy
Advanced Lung Cancer Treatment: ctDNA tumor fraction (TF) is emerging as a selection tool for immunotherapy-based regimens in advanced non-small cell lung cancer. TF of at least 5% predicted greater benefit from ICB plus chemotherapy, although elevated TF also indicated worse outcomes with ICBs alone 42440365Jul. In elderly driver-negative advanced NSCLC, adding thoracic radiotherapy produced nonsignificant gains in PFS and OS while increasing treatment discontinuation, mainly from pneumonia 42121314May. Earlier chemoimmunotherapy administration nearly doubled PFS in LungTIME-C01, but cytotoxic chronopharmacology, circadian immune regulation, and healthcare delivery factors may all contribute 42258320Jun. A retrospective study is also evaluating first-line IO+ChT with TRT in elderly patients with extensive-stage small cell lung cancer 41934389Apr.
Combination Cancer Treatment: Clinical regimens and experimental platforms combine chemotherapy with immune activation, pathway blockade, and spatially controlled delivery. In stage IVB esophageal squamous cell carcinoma, adding radiotherapy to ICT prolonged PFS and OS but markedly increased severe lymphopenia 42504461Jul. Neoadjuvant tislelizumab, nab-paclitaxel, cisplatin, and afatinib produced a 40.6% pCR rate and 82.5% ORR in locally advanced head and neck squamous cell carcinoma, with exploratory immune changes linked to response 42731876Sep. Engineered Escherichia coli Nissle 1917 combined 5-fluorouracil generation with an IL-15 superagonist and PD-L1 blockade, producing systemic antitumor immunity and durable immune memory in murine models 42748218Sep. CDDP/MSA-2@Gel similarly used sustained local release to activate STING and type-I-IFN responses while inhibiting ovarian tumors without systemic toxicity in mice 42456758Jul.
Venetoclax-obinutuzumab-ibrutinib and venetoclax-obinutuzumab produced higher five-year PFS than chemoimmunotherapy in untreated CLL, while overall survival remained similar across treatment arms 41911073Mar. GIV also exceeded GV for PFS, whereas GV and RV produced faster quality-of-life improvements than GIV. Chemoimmunotherapy for relapsed/refractory neuroblastoma produced five-year PFS of 22.6% and OS of 54.7%; most patients surviving at least two years received additional therapy 42487540Jul. In metastatic SMARCA4-deficient thoracic tumors, skeletal muscle metastases occurred in 11.7% of patients and shortened median OS from 18.6 to 13.2 months. STK11 and KRAS mutations were more frequent with skeletal muscle metastases, while first-line chemoimmunotherapy independently predicted outcome 42083275May.
Written from 11 PubMed abstracts, each one cited by PMID above. Published: 2026-09-16. Last written: 2026-09-18 by GPT. Drafted by language models from published abstracts; not medical advice.